Immunoglobulin Market: Key Growth Prospects & Regional Study

By Shruti Vanjare

Immunoglobulins, also termed antibodies, are characterized as glycoprotein molecules produced by plasma or white blood cells. As an integral part of the immune response, immunoglobulins specifically recognize and bind to antigens, thus assisting in their destruction. Since the immune system protects the body from infections, its malfunctioning could lead to various diseases, such as allergy, autoimmunity, and tumors.

According to Inkwood Research, the global immunoglobulin market is forecasted to grow with a CAGR of 6.87% over the estimated years of 2022 to 2030. The market growth is facilitated by the increasing research and development activities, the growing incidence of immunodeficiency diseases and autoimmune disorders, and the rising geriatric population.

Geriatrics & Immunology: The Connecting Thread

The study of immunology is critical to human as well as animal health and, ultimately, their survival. Being at the cutting-edge of medical science, immunoglobulin treatments have led to revolutionizing healthcare developments, including cancer immunotherapy and vaccination.

Moreover, there has been substantial growth in the aging population globally. As per the World Health Organization (WHO), 1 in 6 people worldwide will be aged 60 years or more by 2030. Besides, as per WHO, the share of the population aged 60 years and above is expected to reach 1.4 billion by 2030 from 1 billion in 2020. As people age, their immune system deteriorates and elevates the risk of developing various illnesses. Also, the loss of adaptive immunity makes an individual more susceptible to infections, while reactivating dormant pathogens that were previously suppressed.

In this regard, intravenous immunoglobulin as the mode of delivery can be used for treating a range of conditions impacting the older population, including adult-onset Still’s disease, vasculitis, and certain complications due to Sjögren’s syndrome, among others. This factor also plays an essential role in positioning intravenous immunoglobulin as the largest mode of delivery, expected to capture a revenue share of 81.03% by 2030, as per our analysis.

Regional Analysis –

With an increase in age, there is a concomitant rise in the prevalence of acute infections and cancers. Hence, in order to treat such conditions, the adoption of immunoglobulin products as well as therapies is likely to increase across the globe over the forecast years.

Asia-Pacific:

• The rapid rise in the geriatric population, especially in developing nations such as China, India, and Japan, significantly contributes to the Asia-Pacific immunoglobulin market In this regard, according to our estimations, the Asia-Pacific market is expected to rise with a CAGR of 7.20% during the forecast years.

• Moreover, the significant increase in the geriatric population is expected to elevate the incidence of various diseases due to weakened immune systems. This factor, consequently, is set to bolster the demand for immunoglobulin products, thus fueling the regional market’s growth.

North America:

• As per our evaluations, the North America immunoglobulin market is projected to capture the highest share of 81% by 2030, primarily supplemented by the rising incidence of various diseases and autoimmune conditions.

• According to the Cleveland Clinic, myasthenia gravis, an autoimmune disease, affects men aged 50 to 80 as well as women aged 20 to 40. Moreover, in the United States, the condition is prevalent in approximately 14-40 per 100,000 individuals, thus leading to an increased demand for immunoglobulin-based therapies in the region.

• Treatments for myasthenia gravis concentrate on the improvement of symptoms, with major treatments including monoclonal antibodies, plasma exchange (plasmapheresis), IV immunoglobulin (IVIG), and surgery. Furthermore, Inkwood Research estimates that myasthenia gravis is expected to be the fastest-growing application during the forecast years, progressing with a CAGR of 8.06%.

Immunoglobulin Therapy for Autoimmune Diseases: A Promising Avenue

Immunoglobulins are used for treating various autoimmune diseases such as multiple sclerosis, primary humoral immunodeficiency, autoimmune hemolytic anemia, and immune thrombocytopenic purpura. This primarily boosts the global immunoglobulin market demands.

Moreover, the introduction of human immunoglobulin therapies, as well as their adoption in treating numerous diseases in hospitals and clinics, has reduced the risk of life-threatening infections for patients experiencing immune-related conditions. As per our analysis, this factor also contributes to hospitals & clinics being the dominating end-user over the forecast period.

Key Players’ Contribution | Product Launches and Research & Development

Leading market players such as China Biologic Products Inc, Grifols SA, and Octapharma AG are launching innovative products for the treatment of immune-system-related disorders. For example –

• rhesonativ® by Octapharma AG is used to prevent sensitization in cases where the immune system of the mother may attack the baby’s red blood cells during pregnancy.

• Nanogam 5%, a product launched by Sanquin Plasma Products BV, is used to treat a disrupted immune system, including conditions such as Guillain Barré syndrome, idiopathic thrombocytopenic purpura (ITP), and others.

• ADMA Biologics’ product, BIVIGAM, is an Immune Globulin Intravenous (Human), 10% Liquid, indicated for treating primary humoral immunodeficiency.

Also, strategic initiatives undertaken by market leaders, including expansions, joint ventures, collaborations, partnerships, research & development, help strengthen and expand their customer base. Key players operating in the global immunoglobulin market further enhance their geographical footprint by providing consumers with technologically advanced and innovative offerings, as well.